Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following Infection
Valeria De Giorgi, Kamille A. West, Amanda N. Henning, et al.
The Journal of Infectious Diseases (2021) Vol. 224, Iss. 8, pp. 1294-1304
Open Access | Times Cited: 58

Showing 1-25 of 58 citing articles:

Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients
Yuanling Yu, Meiyu Wang, Xiao‐Ai Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 101
IgG antibodies against SARS-CoV-2 decay but persist 4 months after vaccination in a cohort of healthcare workers
Giulia Brisotto, Elena Muraro, Marcella Montico, et al.
Clinica Chimica Acta (2021) Vol. 523, pp. 476-482
Open Access | Times Cited: 49
Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection
Nickolas Lewis, Laura C. Chambers, Huong T. Chu, et al.
JAMA Network Open (2022) Vol. 5, Iss. 7, pp. e2223917-e2223917
Open Access | Times Cited: 35
SARS-CoV-2—The Role of Natural Immunity: A Narrative Review
Sara Diani, Erika Leonardi, Attilio Cavezzi, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 21, pp. 6272-6272
Open Access | Times Cited: 34
Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort
Shihan Zhang, Ke Xu, Chuchu Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 30
Durability of SARS-CoV-2–Specific T-Cell Responses at 12 Months Postinfection
Zhongyan Lu, Eric D. Laing, Jarina Pena DaMata, et al.
The Journal of Infectious Diseases (2021) Vol. 224, Iss. 12, pp. 2010-2019
Open Access | Times Cited: 35
Long-Term Course of Humoral and Cellular Immune Responses in Outpatients After SARS-CoV-2 Infection
Julia Schiffner, Insa Backhaus, Jens Rimmele, et al.
Frontiers in Public Health (2021) Vol. 9
Open Access | Times Cited: 34
Antibodies against Spike protein correlate with broad autoantigen recognition 8 months post SARS-CoV-2 exposure, and anti-calprotectin autoantibodies associated with better clinical outcomes
Rhiane Moody, Sabrina Sonda, Fay H. Johnston, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 21
Comprehensive Flow Cytometry Profiling of the Immune System in COVID-19 Convalescent Individuals
Sergio Gil-Manso, Iria Miguéns Blanco, Rocío López-Esteban, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 20
Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
Mingtao Liu, Hui Gan, Zhiman Liang, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 13
Assay Harmonization Study To Measure Immune Response to SARS-CoV-2 Infection and Vaccines: a Serology Methods Study
Troy J. Kemp, Heidi Hempel, Yuanji Pan, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 3
Open Access | Times Cited: 12
Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection
Gabriel Siracusano, Chiara Brombin, Claudia Pastori, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 24
Considering epitopes conservity in targeting SARS-CoV-2 mutations in variants: a novel immunoinformatics approach to vaccine design
Mohammad Aref Bagherzadeh, Mohammad Izadi, Kazem Baesi, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 15
Immune repertoire sequencing reveals an abnormal adaptive immune system in COVID‐19 survivors
Jia Chen, Zhiguo Zhou, Wenjing Pan, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Open Access | Times Cited: 15
Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants
Zhaochun Chen, Peng Zhang, Yumiko Matsuoka, et al.
Cell Reports (2022) Vol. 41, Iss. 5, pp. 111528-111528
Open Access | Times Cited: 14
Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants
Zhaochun Chen, Peng Zhang, Yumiko Matsuoka, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 13
Functional Profiling of In Vitro Reactivated Memory B Cells Following Natural SARS-CoV-2 Infection and Gam-COVID-Vac Vaccination
Ekaterina A. Astakhova, Maria G. Byazrova, Gaukhar M. Yusubalieva, et al.
Cells (2022) Vol. 11, Iss. 13, pp. 1991-1991
Open Access | Times Cited: 13
SARS-CoV-2 - The Role of Natural Immunity: A Narrative Review
Sara Diani, Erika Leonardi, Attilio Cavezzi, et al.
(2022)
Open Access | Times Cited: 13
Persistence of the Immune Responses and Cross-Neutralizing Activity With Variants of Concern Following 2 Doses of Adjuvanted SCB-2019 Coronavirus Disease 2019 Vaccine
Peter Richmond, Lara Hatchuel, Filippo Pacciarini, et al.
The Journal of Infectious Diseases (2021)
Open Access | Times Cited: 17
One-Year Follow-Up of COVID-19 Patients Indicates Substantial Assay-Dependent Differences in the Kinetics of SARS-CoV-2 Antibodies
Alexander Egger, Sabina Sahanic, Andreas Gleiß, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 6
Open Access | Times Cited: 10
An ecological study on reinfection rates using a large dataset of RT-qPCR tests for SARS-CoV-2 in Santiago of Chile
Claudio Acuña‐Castillo, Carlos Barrera‐Avalos, Vivienne C. Bachelet, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 5
The benefits and costs of U.S. employer COVID‐19 vaccine mandates
Maddalena Ferranna, Lisa A. Robinson, Daniel Cadarette, et al.
Risk Analysis (2023) Vol. 43, Iss. 10, pp. 2053-2068
Open Access | Times Cited: 4
SARS‐CoV‐2 neutralising antibody therapies: Recent advances and future challenges
Mingtao Liu, Zhiman Liang, Zhangkai J. Cheng, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 5
Closed Access | Times Cited: 4
Benefits of near-universal vaccination and treatment access to manage COVID-19 burden in the United States
Fuhan Yang, Thu Nguyen-Anh Tran, Emily Howerton, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 4
Serological Response and Relationship with Gender-Sensitive Variables among Healthcare Workers after SARS-CoV-2 Vaccination
Roberto Cangemi, Manuela Di Franco, Antonio Angeloni, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 6, pp. 994-994
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top